TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04804293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDA approved ultrasound system with shear wave elastography capability
Description: The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDA approved ultrasound system with shear wave elastography capability
Description: The investigators will acquire at least 4 acquisitions for each of 2 locations on the wrist. The objective is to correlate SWE measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX). Evaluate the treatment response to surgical decompression or corticosteroid injection, using quantitative SWE and correlate the results to repeated patient reported outcomes with Boston CTQ, and objective clinical improvement with Semmes-Weinstein monofilament evaluation for recovery of sensibility, and grip and lateral pinch strength.
Study: NCT06265688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-2051
Description: Investigational drug monotherapy
Study: NCT06540391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB097
Description: Live bacterial therapeutic for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB097
Description: Live bacterial therapeutic for oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Antibiotic
Study: NCT05066854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: integron research
Description: Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Urine samples will be sent to the laboratory for culture and integron PCR according to routine practice.~Results of the integron search will be given to the investigator. Patients in the experimental group with a positive or uninterpretable PCR will also receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.~Patients in the experimental group with a negative PCR will receive a treatment with SXT at the recommended dose.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: usual practice
Description: Patients with suspected UTI with fever will be screened at their admission to the pediatric ED.~Patients in the control group will receive an empirical antibiotic treatment based on the usual practice of each center according to the GPIP guidelines.
Study: NCT06317649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT05050539

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity
Description: 5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity
Description: 5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity
Description: 5 implementation strategies: formal commitments, local champions, implementation blueprint , remind educators (cutting board with WISE EBPs), task-focused facilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity
Description: Low intensity implementation strategies with the addition of holistic individualized facilitation and tailored educational materials.
Study: NCT04849884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORI™ KNEE TENSIONER
Description: Robotic TKA procedure with the REAL INTELLIGENCE™ CORI™ Surgical System including the use of the CORI™ KNEE TENSIONER accessory.
Study: NCT05627050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An Online Augmented Reality (AR) Training Platform
Description: The hardware system is based on camera depth sensor and combined with 3D human tracking technology and intelligent technology, to monitor, correct and record the user's whole body movements in real-time, and the users can follow the training program.
Study: NCT05117112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: XS Muscle Multiplier
Description: Distributed by Amway; this product is a powder, sold in a 6.8 ounce (192g) container.
Study: NCT05279495

Intervention type: DEVICE
Group type: OTHER
Intervention: In a double-blinded fashion, 250 mg CANNAXR cream
Description: Determining the Efficacy of topically applied CANNAXR cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg TOPICAL CBD CANNAXR Cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Topical VEHICLE cream
Description: Determining the Efficacy of topically applied VEHICLE cream in Decreasing UVA Premutagenic and Photoaging markers 8-oxo-dG and the common deletion. 250 mg VEHICLE cream will be randomized for application to a delineated 50 cm2 area of either the left or right, hip/buttocks skin twice daily for 2 weeks
Study: NCT04928144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ - Low concentration
Description: Topical ophthalmic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ - Mid concentration
Description: Topical ophthalmic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ - High concentration
Description: Topical ophthalmic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ - Maximum tolerated
Description: SHJ - Maximum tolerated
Study: NCT06328257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Training
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study: NCT06521047

Intervention type: OTHER
Intervention: NA - Observational study
Description: Observational study, data collection only.

Intervention type: OTHER
Intervention: NA - Observational study
Description: Observational study, data collection only.
Study: NCT06158035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial infusion dose of prophylactic norepinephrine (6 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 ug of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: An initial infusion dose of prophylactic phenylephrine (75 ug) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 12.5 ug of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06289439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea (Camellia sinensis) 1000 mg as extract
Description: Two capsules per day; Each capsule includes Green Tea Leaf (Camellia sinensis) 5000 mg composed of 500 mg of green tea extract and 250 mg of polyphenols (epicatechin (EC), epigallocatechin (EGC), epicatechin gallato (ECG), and epigallocatechin gallato (EGCG))

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules per day; Each capsule includes 100-mg maltodextrin capsules were used as a placebo to match the color and texture of the Green tea tablets to ensure blinding.
Study: NCT06491680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose.~taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose.
Study: NCT06336057

Intervention type: BEHAVIORAL
Intervention: Mentalization
Description: complete several questionnaires including the RFQ (reflective functioning questionnaire) and the MST (Mental states task) which are validated questionnaires about mentalization

Intervention type: BEHAVIORAL
Intervention: Mentalization
Description: complete several questionnaires including the RFQ (reflective functioning questionnaire) and the MST (Mental states task) which are validated questionnaires about mentalization
Study: NCT06573229

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aminolife Plus by Piemme Pharmatech, Italy
Description: A nutritional supplement containing whey protein, vitamin D, carnitine, HMB, perilla, arginine, coenzyme Q10, inositol)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aminolife Plus by Piemme Pharmatech, Italy
Description: A nutritional supplement containing whey protein, vitamin D, carnitine, HMB, perilla, arginine, coenzyme Q10, inositol)
Study: NCT05341791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartoon video describing study information notice
Description: The video will be 20-minutes long, and will consist of graphic depictions (in cartoon style) of the study information content presented in the same flow as the written notice, and explained by a voice-over in the background. The participant will view the video in a quiet room, on a tablet provided by the study staff. The participant will be able to pause the video or rewind it as needed, and view it at his/her desired pace. The video will have an embedded knowledge check at the end of each section, consisting of a background voice asking some questions, pausing (for the participant to think through the correct answers) and then providing the right answers.
Study: NCT05886088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LID104
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Active comparator
Study: NCT05307679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Participants will receive oral basmisanil at age-appropriate dosages

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo
Study: NCT04872387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: Nasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: Nasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: Nasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study: NCT05119075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic OFF-drug state
Description: Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic OFF-drug state
Description: Dopaminergic OFF-drug state: Overnight withdrawal of dopaminergic antiparkinsonian drugs during visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic ON-drug state
Description: Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dopaminergic ON-drug state
Description: Dopaminergic ON-drug state: Patient will be evaluated in his/her regular treatment in dopaminergic ON-drug state at visit 3 or 4. The sequence of drug conditions (dopaminergic OFF-drug/ON-drug state or ON-drug/OFF-drug state) will be randomized.
Study: NCT04939649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A sub-anaesthetic dose of ketamine will be administered for up to a four-week course of twice-weekly infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: A sub-anaesthetic dose of midazolam will be administered for up to a four-week course of twice-weekly infusions.
Study: NCT06222710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacoacupuncture with ultrasound guiding
Description: Physician choose the adequate type and dose of pharmacoacupuncture and needle type with ultrasound guiding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacoacupuncture without ultrasound guiding
Description: Physician choose the adequate type and dose of pharmacoacupuncture and needle type without ultrasound guiding
Study: NCT06386887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16 hours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum feeding for 2 days has been proposed. With this type of intervention, there are no dietary restrictions to the type or quality of food and it decreased daily energy intake by 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of continuous fasting per day for 5 days a week. This will be started 2 days prior to chemotherapy (cycle 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.
Study: NCT05412082

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: MRI-guided pelvic IMRT to the Planning Tumor Volume (PTV) at a dose of 50 Grays (gy) delivered in 25 fractions (fx) over 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU dose of 400 mg/m2 will be administered intravenously (IV) over 5-15 minutes beginning on Day 1; then a dose of 2400 mg/m2 via continual infusion (CI) over 4446-478 hours total dose during Days 1 and 2 of every 14-day cycle, for 4 to 6 cycles.~During SMART TNT Plan I, 5-FU dose of 225 mg/m2 per day will be administered via CI on Day 1 radiation therapy, delivered either 5 or 7 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin dose of 400 mg/m2 bolus will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
Study: NCT05450172

Intervention type: OTHER
Intervention: QoR-15 questionnaire
Description: The QoR-15 is a 15-item questionnaire on postoperative quality of recovery. The DN4 is a 10-item questionnaire on neuropathic pain. Both questionnaires will be given to the patients preoperatively, on postoperative days 2 and 3, and 1, 3 and 6 months after surgery.
Study: NCT05412082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin dose of 85 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 - 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered orally at a dose of 825 mg/m2 via tablet twice per day (BID) on Day 1, 5 days per week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Radiation Therapy
Description: MRI-guided Pelvic accelerated radiation therapy (ART) given over one week at one of the following dose levels :~* Dose level -1: 10 Gy delivered in 4 fractions~* Dose level 0: 12 Gy delivered in 4 fractions~* Dose level 1: 14 Gy delivered in 4 fractions~* Dose level 2: 16 Gy in delivered 4 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan dose of 180 mg/m2 will be administered intravenously (IV) on Day 1 of each 14-day cycle for 4 to 6 cycles, prior to SMART TNT Plan I radiation therapy.
Study: NCT06531824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: BI 690517

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching BI 690517
Description: Placebo matching BI 690517

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 690517
Description: Placebo matching BI 690517

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study: NCT04693533

Intervention type: DRUG
Group type: OTHER
Intervention: Fremanezumab Prefilled Syringe [Ajovy]
Description: The treatment is 225 mg (dissolved in 1.5 ml saline) fremanezumab. Fremanezumab (Ajovy) is a month-long-acting anti-CGRP injection that patients are taught to self-administer at home.
Study: NCT05121441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARD-101
Description: Twice daily, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily, oral administration
Study: NCT06585566

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cortical-shell graft
Description: Retromolar cortical shell graft technique for SABG
Study: NCT06584916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study: NCT06392464

Intervention type: DEVICE
Intervention: Clinical decision support system (software)
Description: Use of a clinical decision support system. Naevia Medical is clinical decision support software (CDSS) that, based on clinical input data (patient history, symptoms, complementary test data, etc.) from adult patients with heart disease, provides healthcare professionals with prioritized, justified, and referenced recommendations and knowledge-related suggestions related to diagnosis, prognosis, and/or treatment (recommended tests, medications, alerts, etc.)
Study: NCT06584916

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04994938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Intervention
Description: Participants will engage in discussions about healthy eating one time per week led by a trained peer leader for 12-weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants will participate in a group exercise session led by a trained peer leader 2-times per week for 12-weeks.
Study: NCT05167864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinumtoxina for Injection
Description: cosmetic injection into the glabella area (eyebrow area)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abobotulinumtoxina for Injection
Description: cosmetic injection into the glabella area (eyebrow area)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IncobotulinumtoxinA for Injection
Description: cosmetic injection into the glabella area (eyebrow area)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrabotulinumtoxinA for Injection
Description: cosmetic injection into the glabella area (eyebrow area)